









市场行情
/
股票
/
nasdaq-crsp
/

CRISPR Therapeutics AG

CRSP

56.250USD

-0.430-0.76%

收盘 12/15, 16:00（美东）报价延迟15分钟

5.28B总市值

亏损市盈率 TTM



CRISPR Therapeutics AG

56.250

-0.430-0.76%

概览公司财务分析

概览

公司

财务

分析

关于 CRISPR Therapeutics AG 公司

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

CRISPR Therapeutics AG简介



公司代码CRSP

公司名称CRISPR Therapeutics AG

上市日期Oct 19, 2016

CEOKulkarni (Samarth)

员工数量393

证券类型Ordinary Share

年结日Oct 19

公司地址Baarerstrasse 14

城市ZUG

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Switzerland

邮编CH-6300

电话41415613279

网址https://crisprtx.com/

公司代码CRSP

上市日期Oct 19, 2016

CEOKulkarni (Samarth)

CRISPR Therapeutics AG公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Samarth Kulkarni, Ph.D.

Chairman of the Board, Chief Executive Officer

339.82K

+18.56%

Dr. Raju Prasad, Ph.D.

Chief Financial Officer

13.01K

+30.05%

Mr. John Thomas Greene

Independent Director

7.00K

Dr. Ali Behbahani, M.D.

Independent Director

270.00

Dr. Briggs W. Morrison, M.D.

Director

Mr. James R. Kasinger, J.D.

General Counsel, Secretary

Dr. Naimish Patel, M.D.

Chief Medical Officer

Mr. Sandesh Mahatme

Independent Director

Dr. Katherine A. High, M.D.

Independent Director

Dr. Maria Fardis, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Samarth Kulkarni, Ph.D.

Chairman of the Board, Chief Executive Officer

339.82K

+18.56%

Dr. Raju Prasad, Ph.D.

Chief Financial Officer

13.01K

+30.05%

Mr. John Thomas Greene

Independent Director

7.00K

Dr. Ali Behbahani, M.D.

Independent Director

270.00

Dr. Briggs W. Morrison, M.D.

Director

Mr. James R. Kasinger, J.D.

General Counsel, Secretary

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

ARK Investment Management LLC

10.27%

BlackRock Institutional Trust Company, N.A.

6.56%

Capital International Investors

5.93%

Orbis Investment Management Ltd.

5.23%

State Street Investment Management (US)

4.20%

其他

67.81%

持股股东

占比

ARK Investment Management LLC

10.27%

BlackRock Institutional Trust Company, N.A.

6.56%

Capital International Investors

5.93%

Orbis Investment Management Ltd.

5.23%

State Street Investment Management (US)

4.20%

其他

67.81%

股东类型

持股股东

占比

Investment Advisor

43.79%

Investment Advisor/Hedge Fund

23.62%

Venture Capital

3.41%

Research Firm

3.14%

Hedge Fund

2.56%

Individual Investor

1.61%

Bank and Trust

0.52%

Pension Fund

0.44%

Sovereign Wealth Fund

0.43%

其他

20.49%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

980

79.52M

84.90%

+75.16K

2025Q3

1019

79.46M

89.59%

+5.57M

2025Q2

986

73.90M

82.20%

+7.69M

2025Q1

943

66.36M

83.61%

-5.70M

2024Q4

951

66.15M

80.53%

+2.60M

2024Q3

955

62.43M

76.50%

+840.55K

2024Q2

969

61.63M

76.06%

+573.40K

2024Q1

979

61.11M

68.18%

+3.34M

2023Q4

980

54.61M

75.07%

+613.05K

2023Q3

983

54.08M

76.54%

+343.99K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

ARK Investment Management LLC

10.18M

11.2%

+17.19K

+0.17%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.42M

5.96%

+3.00M

+124.40%

Jun 30, 2025

Capital International Investors

5.59M

6.15%

-479.37K

-7.89%

Jun 30, 2025

Orbis Investment Management Ltd.

2.76M

3.04%

+1.20M

+76.88%

Jun 30, 2025

State Street Investment Management (US)

3.27M

3.6%

+859.33K

+35.64%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

3.68M

4.05%

-115.08K

-3.03%

Jun 30, 2025

The Vanguard Group, Inc.

2.28M

2.51%

+528.38K

+30.18%

Jun 30, 2025

UBS Financial Services, Inc.

2.59M

2.85%

+859.43K

+49.73%

Jun 30, 2025

Amova Asset Management Co., Ltd.

2.41M

2.66%

-125.05K

-4.92%

Jun 30, 2025

Amova Asset Management Americas, Inc

2.41M

2.65%

-125.62K

-4.95%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Genomic Revolution ETF

10.33%

Global X Genomics & Biotechnology ETF

5.71%

ARK Innovation ETF

5.12%

AXS Green Alpha ETF

4.84%

WisdomTree BioRevolution Fund

2.81%

Virtus LifeSci Biotech Products ETF

2.48%

State Street SPDR S&P Biotech ETF

2.41%

Direxion Daily S&P Biotech Bull 3X Shares

1.48%

Franklin Genomic Advancements ETF

0.92%

ProShares Ultra Nasdaq Biotechnology

0.59%

ARK Genomic Revolution ETF

占比10.33%

Global X Genomics & Biotechnology ETF

占比5.71%

ARK Innovation ETF

占比5.12%

AXS Green Alpha ETF

占比4.84%

WisdomTree BioRevolution Fund

占比2.81%

Virtus LifeSci Biotech Products ETF

占比2.48%

State Street SPDR S&P Biotech ETF

占比2.41%

Direxion Daily S&P Biotech Bull 3X Shares

占比1.48%

Franklin Genomic Advancements ETF

占比0.92%

ProShares Ultra Nasdaq Biotechnology

占比0.59%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

CRISPR Therapeutics AG的前五大股东是谁？



CRISPR Therapeutics AG 的前五大股东如下：
ARK Investment Management LLC持有股份：10.18M，占总股份比例：11.20%。
BlackRock Institutional Trust Company, N.A.持有股份：5.42M，占总股份比例：5.96%。
Capital International Investors持有股份：5.59M，占总股份比例：6.15%。
Orbis Investment Management Ltd.持有股份：2.76M，占总股份比例：3.04%。
State Street Investment Management (US)持有股份：3.27M，占总股份比例：3.60%。